

Immunotherapy of childhood cancer

Presidents:

Prof. Franco Locatelli

Prof. Lorenzo Moretta

Prof. Andrea Pession

Promoted by



FONDAZIONE INTERNAZIONALE





Co-Presidents of the meeting

Franco Locatelli

University of Pavia Department of Pediatric Hematology and Oncology Bambino Gesù Children's Hospital, Rome, Italy

Lorenzo Moretta

Immunology Area Bambino Gesù Children's Hospital, Rome, Italy

Andrea Pession

Paediatrics Unit Sant'Orsola Academic Hospital Alma Mater Studiorum Università di Bologna, Italy

Promoted by

Fondazione Internazionale Menarini

Centro Direzionale Milanofiori Edificio L - Strada 6 20089 Rozzano, Milan (Italy) Phone: +39 02 55308110 Fax: +39 02 55305739 milan@fondazione-menarini.it www.fondazione-menarini.it

Organizing Secretariat

DueCi Promotion srl

Via C. Farini, 28 40124 Bologna (Italy) Phone: +39 051 4841310 Fax: +39 051 247165 ggrillenzoni@duecipromotion.com www.duecipromotion.com

Under the auspices of





02:30 PM	Registration
03:30 PM	Opening remarks, F. Locatelli, L. Moretta, A. Pession Welcome address by the Authorities of the Bambino Gesù Children's Hospital Rome
04:00 PM	State of the art on immunotherapy of childhood cancer F. Locatelli, L. Moretta, A. Pession
Chairmen:	Session I Cellular and molecular basis of cancer immunotherapy A. Bacigalupo, F. Locatelli
05:00 PM	Antibody engineering for specific recognition and enhanced effector function, Antonio Lanzavecchia
05:30 PM	NK cells: from surface receptors to the therapy of high risk leukemia, Lorenzo Moretta
06:00 PM	Immune checkpoints in human NK cells Alessandro Moretta
06:30 PM	Innate lymphoid cells and cancer, Eric Vivier
07:00 PM	Discussion
07:30 PM	Welcome cocktail
Chairpersons:	Session II Cell-based therapies of haemopoietic malignancies B. Dallapiccola, A. Santoni
08:30 AM	Alloreactive T cells for the treatment of hematological malignancies, Fred Falkenburg
09:00 AM	Strategies to harness both innate and adaptive immunity after allogeneic HSCT, Franco Locatelli
09:30 AM	CIK cells, Eva Rettinger
10:00 AM	Harnessing T memory stem cells for adoptive cell transfer therapy of cancer, Luca Gattinoni
10:30 AM	Discussion
10:50 AM	Coffee break

Session III Antibodies in the therapy of haemopoietic malignancies (I) Chairpersons: F. Fagioli, A. Pession Naked antibody for treatment of ALL 11:20 AM Peter Lang The antibody-drug conjugate Inotuzumab for adult ALL 11:50 AM Giovanni Martinelli The antibody-drug conjugate Inotuzumab for 12:20 AM childhood ALL, Inge van der Sluis 12:50 AM Anti-CD38 monoclonal antibodies. Lia Gore 01:20 PM Discussion 01:40 PM Lunch Antibodies in the therapy of haemopoietic malignancies (II) G. Basso, A. Biondi Chairmen: Potent anti-tumor activity by anti-PD-1 Abs 02:30 PM acting independently of PD-1/PDL-1 interaction Giuseppe Pantaleo 03:00 PM PD-1 and PD-1 ligands: from discovery to clinical application, Michele Maio The antibody-drug conjugate Brentuximab 03:30 PM Vedotin for childhood lymphomas Christine Mauz-Körholz 04:00 PM Discussion 04:15 PM Coffee break 04:45 PM **Epratuzumab for treatment of relapsed ALL** Arend Von Stackelberg Bi-specific T cell engager for adult ALL 05:15 PM Gerhard Zugmaier Blinatumomab for childhood ALL, Pietro Merli 05:45 PM 06:15 PM Discussion

10th

ovemb

Chairmen:	Role of microbiota in cancer immunotherapy L. Moretta, V. Pistoia
08:00 AM	Microbes and cancer: carcinogenesis and therapy Giorgio Trinchieri
08:45 AM	The role of the intestinal microbiome in allogeneic hematopoietic cell transplantation Marcel van den Brink
09:15 AM	Discussion
Chairmen:	Session V Genetically-modified T cells in the therapy of haemopoietic malignancies G. Arcese, E. Proietti
09:40 AM	CAR T cells for ALL- CD19 and beyond Sara Ghorashian
10:10 AM	CAR T cells for CD19+ leukemia: the global trial experience Jochen Büchner
10:40 AM	CAR T cells for AML, the CD44v6-targeting approach Attilio Bondanza
11:10 AM	Discussion
11:30 AM	Coffee break

Session IV

ber 11 th	Chairpersons:	Session VI Genetically-modified T cells in the therapy of haemopoietic malignancies and solid tumor E. Maggi, M.C. Mingari
Saturday, November 11 th	11:50 AM	CAR T cells for neuroblastoma, Ignazio Caruana
	12:20 AM	CAR T cells for childhood brain tumors, Concetta Quintarelli
	12:50 AM	T cells genetically modified with artificial TCRs for hematological malignancies Chiara Bonini
S	01:20 PM	Discussion
	01:40 PM	Light lunch
	02:20 PM	Take home message: F. Locatelli, L. Moretta, A. Pession
	02:45 PM	Closing remarks: F. Locatelli, L. Moretta, A. Pession

End of the meeting

03:15 PM

Arcese William

Hematology Department, Stem Cell Transplant Unit and Rome Transplant Network, University "Tor Vergata", Roma, Italy

Bacigalupo Andrea

Institute of Hematology, Policlinico Gemelli, Università del Sacro Cuore, Roma, Italy

Basso Giuseppe

Pediatric Oncology Hematology Division, Woman's and Child's Health Department, University Hospital of Padova, Italy

Biondi Andrea

Department of Pediatrics, University of Milano-Bicocca, Milano, Italy

Bondanza Attilio

San Raffaele University Hospital and Scientific Institute, Milano, Italy

Bonini Chiara

University Vita-Salute San Raffaele, Ospedale San Raffaele Scientific Institute, Milano, Italy

Büchner Jochen

Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway

Caruana Ignazio

Department of Paediatric Haematology and Oncology, Bambino Gesù Children's Hospital, Roma, Italy

Dallapiccola Bruno

Scientific Directorate, Bambino Gesù Children's Hospital, Roma, Italy

Fagioli Franca

Pediatric Sciences, AOU Città della Salute e della Scienza di Torino, Italy

Falkenburg Johan

Department of Hematology, Leiden University Medical Center, The Netherlands

Gattinoni Luca

Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA

Ghorashian Sara

Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, UK

Gore Lia

Department of Pediatric Hematology, Oncology, Bone Marrow Transplant, University of Colorado School of Medicine, Aurora, Colorado, USA

Lang Peter

Department Hematology-Oncology, University Children's Hospital Tüebingen, Germany

Lanzavecchia Antonio

Institute for Research in Biomedicine, Bellinzona, Switzerland

Locatelli Franco

University of Pavia, Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, Roma, Italy

Maggi Enrico

Internal Medicine, Department of Experimental and Clinical Medicine, University of Firenze, Italy

Maio Michele

Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Italy

Martinelli Giovanni

Istituto di Ematologia "Seràgnoli", Università di Bologna, Italy

Mauz-Körholz Christine

Department of Pediatric Hematology and Oncology, Justus Liebig University of Giessen, Germany

Merli Pietro

FACULT

Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, Roma, Italy

Mingari Maria Cristina

Department of Experimental Medicine, Laboratory of Immunology, IRCCS Ospedale Policlinico San Martino, Genova, Italy

Moretta Alessandro

Molecular Immunology Labs, Department of Experimental Medicine and Center of Excellence for Biomedical Research, University of Genova, Italy

Moretta Lorenzo

Immunology Area, Bambino Gesù Children's Hospital, Roma, Italy

Pantaleo Giuseppe

Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, CHUV, Lausanne, Switzerland

Pession Andrea

Paediatrics Unit Sant'Orsola Academic Hospital, Alma Mater Studiorum Università di Bologna, Italy

Pistoia Vito

Immunology Area, Bambino Gesù Children's Hospital, Roma, Italy

Projetti Enrico

Unità Operativa Immunologia dei Tumori, Dipartimento di Oncologia e Medicina Molecolare Istituto Superiore di Sanità, Roma, Italy

Quintarelli Concetta

Department of Onco-haematology, Cell and gene therapy for paediatric tumors, Bambino Gesù Children's Hospital, Roma, Italy

Rettinger Eva

Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, Frankfurt, Germany

Santoni Angela

Department of Molecular Medicine, Sapienza University, Roma, Italy

Trinchieri Giorgio

Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA

Van den Brink Marcel

Division of Hematologic Oncology, Memorial Sloan, Kettering Cancer Center, New York, USA

Van der Sluis Inge

ErasmusMC, Sophia Children's Hospital, Rotterdam and Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

Vivier Eric

Director, Centre d'Immunologie de Marseille-Luminy, France

Von Stackelberg Arend

Pediatric Oncology/Hematology, Charité Universitätsmedizin Berlin, Germany

Zugmaier Gerhard

Global Clinical Development, Amgen Research, Munich, Germany

Meeting venue

The venue for the symposium is **Domus del Circo Massimo**Via dei Cerchi 87/89
Roma, Italy
www.domuscircomassimo.com

Secretariat during the meeting

The Secretariat will be open at the following times:

Thursday November 9^{th} from 01:30 p.m. to $0\overline{7}$:30 p.m. Friday November 10^{th} from 07:30 a.m. to 06:30 p.m. Saturday November 11^{th} from 07:30 a.m. to 03:00 p.m.

Official language

The official language of the meeting is English. Simultaneous translation will not be provided.

Attendees' registration

The symposium is free to attend, but on line registration is required. For registration and information, please link to: www.en.fondazione-menarini.it

Or contact ggrillenzoni@duecipromotion.com

On line registrations will be accepted on a first-come, first-served basis and may be closed in advance whenever the maximum number of participants allowed in the venue will be reached.

The registration includes:

access to scientific sessions, welcome reception, coffee breaks, lunch, program book, certificate of attendance.

notes

Fondazione Internazionale Menarini

Symposia: n. 359

